益方生物：2025前三季度营收大增173.86%

Core Insights - Yifang Bio reported a significant increase in revenue for Q3, achieving 11.73 million yuan, a year-on-year increase of 173.86% [1] - For the first three quarters, the company generated a total revenue of 30.89 million yuan, reflecting a year-on-year growth of 61.27% [1] - The company reported a net loss attributable to shareholders of 61.81 million yuan for the reporting period, an improvement from a loss of 91.09 million yuan in the same period last year, reducing the loss by 29.28 million yuan [1] - Year-to-date, the net loss attributable to shareholders reached 181 million yuan, a reduction of 124 million yuan compared to the previous year [1] Revenue and Profit Analysis - The revenue for the reporting period primarily consisted of recognized income from technology licensing and cooperation [1] - R&D expenses decreased by 35.86% year-on-year due to reduced investment related to the clinical trial of Gsorese, which is expected to conclude in 2024 [1]